Go to deals
Healthcare

Open Orphan has successfully raised capital in an oversubscribed fundraise

Open Orphan Plc has completed an equity placing to raise US$15.5 million to maximize available COVID-19 opportunities and testing.

Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Open Orphan comprises of two commercial specialist CRO services businesses: hVIVO and Venn Life Sciences, and has offices in London, Dublin, Paris and the Netherlands. The company is led by a management team with deep industry and financial experience.

Oaklins Cavendish’s sister firm finnCap, based in the UK, advised Open Orphan Plc on its oversubscribed equity fundraising of US$15.5 million.

Talk to the deal team

 Geoff  Nash

Geoff Nash

Director
London, United Kingdom
Oaklins Cavendish

Related deals

PCI Pal has completed an equity raise
Financial Services | TMT

PCI Pal has completed an equity raise

PCI Pal has completed a fundraising. Funds will be allocated towards several key areas, with a significant portion directed towards supporting its continued expansion in the US, focusing on marketing efforts, product marketing and enhancing engagement with key partners.

Learn more
Prestige Inhome Care has found a long-term strategic partner
Healthcare

Prestige Inhome Care has found a long-term strategic partner

Prestige Inhome Care has received a growth capital investment from Yorkway Private. The newly formed partnership will provide growth capital for geographic expansion, increasing Prestige’s range of services and potential future acquisitions. The investment in Prestige is in line with Yorkway’s mandate to invest in leading Australian mid-market companies with strong management teams, backed by significant growth tail winds, as is the case in the aged care industry.

Learn more
Cara Care has been acquired by Mahana Therapeutics
Private Equity | Healthcare | TMT

Cara Care has been acquired by Mahana Therapeutics

Mahana Therapeutics Inc., renowned for its pioneering digital treatments targeting chronic health issues, has recently finalized the acquisition of Cara Care (HiDoc Technologies GmbH). Cara Care stands out as a premier digital health platform and an official digital health application (DiGA) dedicated to enhancing gut health. This acquisition, supported by key investors Lux Capital and Jazz Ventures Partners, perfectly aligns with Mahana’s expansion strategy.

Learn more